2014 Archive


Results presented in poster presentation beginning today and in oral presentation Saturday November 8 at 1:40 PM at Society for Immunotherapy of Cancer annual meeting. ANN ARBOR, Mich. – November 7, 2014 – Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the… Read More

Novel, Synthetic RORγ Agonist Compounds as a Potential Anti-Cancer Approach… Read More

Data to be presented in poster presentation beginning Friday November 7; selected for oral presentation Saturday November 8 at 1:40 PM in Exhibit Hall C. ANN ARBOR, Mich. – October 31, 2014 – Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the… Read More

F1F0-ATPase Modulation Is Efficacious in Models in IBD and Induces Apoptosis of Human CCR9+ Gut-Tropic T-cells… Read More

Modulation of the F1F0-ATPase Induces Apoptosis of Mouse and Human Lamina Propria T-cells and Is Efficacious in Models of IBD… Read More

ANN ARBOR, Mich. – August 8, 2014 – Lycera Corp., a biopharmaceutical company pioneering the development of breakthrough oral medicines to treat autoimmune disease and cancer based on the science of immune modulation, today announced the appointment of Harinder Singh, Ph.D., as chair of the company’s scientific advisory board. Dr. Singh will lead the board’s… Read More